Glioblastoma mesenchymal subtype enhances antioxidant defence to reduce susceptibility to ferroptosis-Reference-Cited by-同舟云学术

Glioblastoma mesenchymal subtype enhances antioxidant defence to reduce susceptibility to ferroptosis

Published:2024-09-05 Issue:1 Volume:14 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

D’Aprile Simona,Denaro Simona,Lavoro Alessandro,Candido Saverio,Giallongo Sebastiano,Torrisi Filippo,Salvatorelli Lucia,Lazzarino Giacomo,Amorini Angela Maria,Lazzarino Giuseppe,Magro Gaetano,Tibullo Daniele,Libra Massimo,Giallongo Cesarina,Vicario Nunzio,Parenti Rosalba

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41598-024-72024-8.pdf

Reference68 articles.

1. Wirsching, H. G., Galanis, E. & Weller, M. Glioblastoma. Handb. Clin. Neurol. 134, 381–397. https://doi.org/10.1016/B978-0-12-802997-8.00023-2 (2016).

2. Torrisi, F. et al. Epigenetics and metabolism reprogramming interplay into glioblastoma: Novel insights on immunosuppressive mechanisms. Antioxidants 12, 220. https://doi.org/10.3390/antiox12020220 (2023).

3. Wen, P. Y. et al. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 22, 1073–1113. https://doi.org/10.1093/neuonc/noaa106 (2020).

4. Fabro, F., Lamfers, M. L. M. & Leenstra, S. Advancements, challenges, and future directions in tackling glioblastoma resistance to small kinase inhibitors. Cancers 14, 600. https://doi.org/10.3390/cancers14030600 (2022).

5. Torrisi, F. et al. The hallmarks of glioblastoma: Heterogeneity, intercellular crosstalk and molecular signature of invasiveness and progression. Biomedicines 10, 806. https://doi.org/10.3390/biomedicines10040806 (2022).